Loading stock data…
ENLV
$0.69-0.02 (-3.02%)
After Hours$0.69+0.00 (+0.00%)· Last close Jun 9
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Enlivex Ltd. in the Healthcare sector is trading at $0.69 with a market capitalization of $205M. Wall Street consensus targets $20.00 (1 analysts), implying a +2787.7% move over the next 12 months. The stock is currently near its 52-week low of $0.66, remaining 29.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +2787.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$0.69
Potential Upside
91028.5%
Whystock Fair Value$631.16
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$20.00+2787.7%
Range$20.00 – $20.00
Fundamentals
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM int...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$204.89M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
0.03
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.49
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
63.85%
Volume
Today's trading volume
355,537
Recent News
Enlivex advances Allocetra while expanding into prediction markets
Enlivex CEO Oren Hershlovitz joined Steve Darling from Proactive to discuss the company’s dual strategy of advancing late-stage clinical drug development while building a digital asset treasury initiative tied to decentralized prediction markets. Hershkovitz explained that Enlivex continues progressing development of Allocetra for osteoarthritis while simultaneously gaining exposure to the growing prediction market sector through the RAIN token ecosystem. The company completed a transformative transaction at the end of 2025 that established a treasury strategy centered around the RAIN protocol, which management describes as a decentralized prediction market platform. Enlivex invested more than $200 million in RAIN tokens and also secured an exclusive option to acquire additional tokens at a fixed price. Hershkovitz said the structure provides shareholders with significant upside exposure tied to the future growth of the protocol and broader adoption of decentralized prediction markets. On the clinical side, Enlivex continues advancing Allocetra™ for knee osteoarthritis. The company previously completed a Phase 2a double-blind, placebo-controlled study that demonstrated statistically significant improvements in pain reduction and functional outcomes among patients over the age of 64. Enlivex has now received authorization from the U.S. Food and Drug Administration to begin a Phase 2b study and has also secured Clinical Trial Application approval in Denmark. Topline results from the Phase 2b trial are expected in the first half of 2027 and could support advancement into Phase 3 development. The company believes its combination of biotechnology development and strategic exposure to emerging digital asset infrastructure creates a differentiated growth profile as both sectors continue to evolve. #proactiveinvestors #enlivixltd #nasdaq #enlv #Biotech #Allocetra #Osteoarthritis #ClinicalTrials #PredictionMarkets #DigitalAssets #RAINToken #HealthcareInnovation
H.C. Wainwright Highlight Improved Balance Sheet Supporting Enlivex Ltd. (ENLV) Outlook
We recently compiled a list of the 8 Oversold Biotech Stocks to Invest In Now. Enlivex Ltd. is one of the oversold stocksto invest in now. TheFly reported on April 7 that H.C. Wainwright increased its price target on ENLV from $13 to $20 while maintaining a Buy rating. The firm noted that the company […]
Enlivex Therapeutics Q4 Earnings Call Highlights
Enlivex Therapeutics (NASDAQ:ENLV) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline what they described as a “dual-engine” strategy that combines clinical-stage drug development with a digital-asset treasury focused on decentralized prediction markets. Executi
Enlivex Therapeutics announces new listing of RAIN token on Kraken
Enlivex Therapeutics (ENLV) reported that its primary treasury asset, the RAIN token, has been listed on the Kraken cryptocurrency exchange effective February 9, 2026, further expanding access to the token across an additional digital asset trading platform.President's Day Sale - 70% OffUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Published first on TheFl
Nasdaq biotech firm bets $212m on new Arbitrum-based prediction market
Biopharma firm sets its sights on Rain Protocol’s native token. Rain is an Arbitrum-based prediction market protocol. Prediction markets tipped to reach $96 billion in 10 years.